跳至主要内容
临床试验/NCT01103180
NCT01103180终止2 期

SSRIs and Self-harm in Borderline Personality Disorder

University of Chicago1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
70
试验地点
1
主要终点
Self-harm Ideation

研究概览

简要总结

The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Borderline Personality Disorder
  • Current Major Depression

排除标准

  • Past 2 months SSRI use
  • Past 6 months non-SSRI antidepressant use
  • Past 2 months initiation of psychotherapy
  • Lifetime bipolar disorder, organic disorder, psychotic disorder
  • Current alcohol or drug dependence
  • Current severe suicidal / homicidal ideation necessitating immediate medical intervention
  • Currently pregnancy or nursing
  • Unable or unwilling to cooperate with study protocol

研究组 & 干预措施

Escitalopram

Experimental

10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)

干预措施: Escitalopram (Drug)

Placebo

Placebo Comparator

Inert placebo (sugar pill) taken daily for eight weeks

干预措施: Escitalopram (Drug)

结局指标

主要结局

Self-harm Ideation

时间窗: pre-treatment (week 0) to post-treatment (end of week 8)

Self-harm ideation was measured by electronic diaries (EMA) up to four times a day. Each time a person completed an EMA diary they were asked to rate their urge to hurt themselves on a 5 point scale ( 0 to 4) pad where 0 is not at all, 2 is moderately and 4 is extremely strong.

次要结局

  • Depressive Symptoms(baseline (week 0) and post treatment (week 8).)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验